Preclinical assessment of LCAR-B38M, a novel BCMA-targeting chimeric antigen receptor (CAR)-T cell therapy in relapsed/refractory multiple myeloma

Authors :: Jiaying Hao
Zhao Yuncheng
Zhuang Qiuchuan
Fan Xiaohu
Lei Yang
Dan Zhao
Wang Pingyan
Dong Geng
Source :: Clinical Lymphoma Myeloma and Leukemia. 19:e160
Publication Year :: 2019
Publisher :: Elsevier BV, 2019.

Subjects :: Cancer Research
Oncology
business.industry
Relapsed refractory
Cancer research
Medicine
CAR T-cell therapy
Hematology
business
medicine.disease
Chimeric antigen receptor
Multiple myeloma

Full Text Access

Tools